TRIM33 and cancer: While anti-CCAR1 and anti-Sp4 appear to be the most common ‘cancer-modifier’ autoantibodies in anti-TIF1γ-positive DM, others have been described and an increasing diversity of the autoimmune response appears to be associated with a reduced likelihood of cancer emergence [37].